Home
Press releases
Press releases
Recent press, briefings and insights helping you stay informed on AliveDx newest launch.
-
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
JERSEY, Channel Islands, Feb. 14, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray. “We are very
-
Quotient Announces Positive Preliminary Results from the Initial Serological Disease Screening US Field Trial
“We are very encouraged by these results. The Initial SDS and the Expanded Immunohematology Microarray will be the first powerful commercial combination to hit the market. These results continue to demonstrate the effectiveness of the MosaiQ™ platform,” said Franz Walt, CEO
-
Quotient Limited Announces the Submission of the Initial SDS Microarray CE mark Filing for MosaiQ™
“The timely submission of our initial SDS microarray is yet another major step for the Company, advancing our efforts to demonstrate the effectiveness of MosaiQ in the transfusion diagnostics marketplace. The next steps include the submission of the initial SDS
-
Quotient Limited Receives European CE Mark for its Initial IH Microarray
Initial IH Microarray Approval in Europe Following the successful conclusion of its first EU field trial in July 2018 and the subsequent submission of the technical dossier for CE Mark approval in late September 2018, on April 30, 2019, the Company was informed that it had
-
Quotient Limited Announces Initial SDS EU Field Trial Performance Data for MosaiQ™
Initial SDS Microarray – Field Trial Assay Performance Field trial results for the initial MosaiQ SDS Microarray used for the detection of CMV and Syphilis achieved the required clinical performance. The field trial data was obtained by donor center testing
